Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05097131
Other study ID # US-ALZ-11855
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 18, 2021
Est. completion date May 20, 2022

Study information

Verified date April 2023
Source Biogen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.


Recruitment information / eligibility

Status Terminated
Enrollment 29
Est. completion date May 20, 2022
Est. primary completion date May 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Participant has a diagnosis of Alzheimer's Disease (AD) and is prescribed aducanumab-avwa by their treating physician. - Participant's treating physician has made the decision to initiate aducanumab-avwa prior to participant inclusion and independently of the purpose of the study. Key Exclusion Criteria: - Participant concurrently participates in any interventional clinical study. - Participant has ever been treated with aducanumab-avwa at a dose of 3 milligrams per kilogram (mg/kg) or greater prior to signing ICF. - Participant has ever been treated with aducanumab-avwa and discontinued treatment prior to signing ICF. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Abington Neurological Associates Abington Pennsylvania
United States Carolina Clinical Research & Consulting, LLC Asheboro North Carolina
United States The Memory Clinic Bennington Vermont
United States Research Site Boca Raton Florida
United States Research Site Bradenton Florida
United States Research Site Canton Ohio
United States Dayton Center for Neurological Associates Centerville Ohio
United States Northwest Neurology Chicago Illinois
United States Research Site Chula Vista California
United States New Life Medical Research Center, Inc Hialeah Florida
United States Genesis Neuroscience Clinic Knoxville Tennessee
United States Las Vegas Medical Research Las Vegas Nevada
United States Research Site Matthews North Carolina
United States Miami Jewish Health System, Inc Miami Florida
United States Research Site Ozark Missouri
United States Imic, Inc. Palmetto Bay Florida
United States South Shore Neurologic Associates, P.A. Patchogue New York
United States Neurostudies, Inc Port Charlotte Florida
United States Coastal Neurology, PA Port Royal South Carolina
United States Center for Cognitive Health Portland Oregon
United States Mehdi Meratee MD Valencia California
United States Vero Beach Neurology and Research Institute Vero Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Biogen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Quick Dementia Rating Scale Informant Version & Patient Version (QDRS-IV/PV) Score QDRS-IV /PV is rapid dementia staging tool. It is a 10-item questionnaire completed by an informant and a participant. The 10 domains covered are memory and recall, orientation, decision-making and problem-solving abilities, activities outside the home, function at home and hobbies, toileting and personal hygiene, behavior and personality changes, language and communication abilities, mood, and attention and concentration. Each domain is rated on five-point scale with increasing severity of symptoms. Total scores range from 0 to 30 with higher scores representing greater cognitive impairment. Up to 5 years
Primary Change from Baseline in Amsterdam Instrumental Activities of Daily Living Questionnaire Short Version (A-IADL-Q-SV) Score A-IADL-Q-SV is used to measure activities of daily living (ADL) in earliest stages of dementia. It consist of 30 items in 7 categories. All items are rated on a five-point scale, ranging from 'no difficulty' to 'unable to perform'. Scoring is based on item response theory (IRT). A-IADL-Q-SV meet all the basic assumptions of IRT scoring, based on a Graded Response Model: (1) Unidimensionality, which implies that one underlying latent trait determines the items; (2) Local independence, meaning the independence of item responses, conditional on the latent trait; and (3) Monotonicity, meaning the probability of endorsing higher item categories as the trait level increases. The IRT latent trait levels are transformed into a 'T-score' with a range from approximately 20 to 80, a mean of 50 and a standard deviation of 10, with higher 'T-scores' indicating better IADL functioning. Up to 5 years
Primary Change from Baseline in Functional Activities Questionnaire (FAQ) Score FAQ is a 10-item questionnaire designed to assess independence in participants with Alzheimer's Disease by measuring instrumental activities of daily living. Each question is rated on a 4-point Likert scale (0 = normal to 3 = dependent). Total score ranges from 0 to 30 with higher scores indicating more impairment. Up to 5 years
Primary Change from Baseline in Montreal Cognitive Assessment Version 8.1 (MoCA v8.1) Score It is used to detect mild cognitive dysfunction. It assesses 30 items in different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total score ranges from 0-30 with lower score indicating poor performance. Up to 5 years
Primary Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score The NPI-Q assesses twelve behavioral domains common in dementia including; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep/night-time behavior change, and appetite/eating change. The questionnaire is given by the clinician to the patient's caregiver who is asked if the behavior described is present in the patient. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale (1 = mild, 2= moderate, and 3= severe) and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale (0 = not distressing at all, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme or very severe). The total severity score represents the sum of individual scores and ranges from 0 to 36. The total distress score represents the sum of individual symptom scores and ranges from 0 to 60. Baseline up to 5 years
Primary Change from Baseline in Geriatric Depression Scale Short Form (GDS-SF) Score This is the screening test for depression in elderly people. The questionnaire contains 15 items. Participants indicate the presence or absence of each symptom. The GDS-SF score is the total number of positive depressive items. Score range is from 0-15. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 indicate moderate depression and 12-15 indicate severe depression. Up to 5 years
Primary Change from Baseline in 13-Item Quality of Life in Alzheimer's Disease (QoL-AD) Score The scale includes 13 items of life domains including the participant's physical health, mood, relationships, activities, and ability to complete tasks. Each item is scored using a scale of 1-4 (poor, fair, good, or excellent). Total score ranges 13-52; higher scores indicate better QOL. Up to 5 years
Primary Change from Baseline in Zarit Burden Interview (22-Item) Score This assesses the level of burden experienced by the principal caregivers of older participants with senile dementia and disabled participants. It consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. Up to 5 years
Primary Change from Baseline in Short Form 12 Version 2 (SF-12v2) Score It is an alternative to Short Form 36 (SF-36®) for use in large surveys of general and specific populations as well as large longitudinal studies of health outcomes. It consists of eight subscale scores (physical functioning [PF], role-physical [RP], bodily pain [BP], general health [GH], vitality [VT], social functioning [SF], role-emotional [RE], and mental health [MH]). Total score ranges from 0 to 100. Higher scores indicate better health status. Up to 5 years
Primary Change from Baseline in Health Care Resource Utilization (HCRU) Using Resource Utilization in Dementia Lite (RUD Lite) Measures HCRU among older adults with dementia and their caregivers, and time spent on formal and informal care by caregivers. This questionnaire is not scored, it provides information, such as, hospitalizations, time spent assisting with personal ADLs, time spent supervising the participant, social services. Up to 5 years
Primary Change form Baseline in Patient Global Impressions Scale of Severity (PGI-S) Score PGI-S evaluates the severity of participant's condition. PGI -S is a 1-item questionnaire where the response is recorded on a 4-point scale scored as: "normal" (1), "mild" (2), "moderate" (3), or "severe" (4). Up to 5 years
Primary Change from Baseline in Patient Global Impression of Change (PGI -C) Score PGI-C is a 7-point self-administered scale that assesses if there has been a change in the participant's health over time. Participants will rate their change as "1=very much improved," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse". Up to 5 years
Secondary The Number of Participants With Adverse Events (AEs), Including Amyloid-Related Imaging Abnormality (ARIA), andSerious Adverse Events (SAEs) in Aducanumab-avwa-treated Participants in Real-world Per Label Recommendation An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of amedicinal product, whether or not related to the medicinal product. An SAE is any untoward medical occurrence thatat any dose: results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event) requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent orsignificant disability/incapacity, results in a congenital anomaly/birth defect, is a medically important event. Up to 5 years
Secondary To Obtain Descriptive Statistics on the Characteristics of the Aducanumab-avwa User Population and on Drug Utilization Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT02409082 - Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures N/A
Terminated NCT02565511 - A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Phase 2/Phase 3
Completed NCT01993836 - Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Phase 4
Completed NCT00448799 - Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls Phase 1
Recruiting NCT04639050 - Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT06424236 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Phase 2/Phase 3
Active, not recruiting NCT05891496 - A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Phase 3
Terminated NCT01723488 - A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 Phase 0
Terminated NCT01733355 - A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807 Phase 0
Completed NCT00911690 - Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders N/A
Recruiting NCT01479855 - Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type N/A
Completed NCT01469351 - Identifying Potential Effects of Liraglutide on Degenerative Changes N/A
Completed NCT00439010 - Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects Phase 1
Recruiting NCT05269394 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Phase 2/Phase 3
Recruiting NCT01760005 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Phase 2/Phase 3
Completed NCT04623242 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Phase 2/Phase 3
Suspended NCT05552157 - A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Phase 2/Phase 3
Completed NCT04023994 - A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants Phase 1
Terminated NCT03131453 - A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Phase 2/Phase 3
Completed NCT01946243 - The Feasibility of Florbetapir Quantitation Phase 4